According to new research published in The Lancet Diabetes & Endocrinology.
16 participants received a placebo according to the same timetable. The researchers found no significant difference between the two groupings according to the measure, but there were some notable differences between the combined groupings when the secondary outcomes were analysed. Using the same way of measuring insulin secretion four hours after eating, there is a significant difference between the study and control group: the group who received alefacept demonstrated preserved insulin secretion, whereas insulin secretion in the placebo group reduced. Related StoriesBetalin launches fresh EMP technology that could transform diabetes treatmentDiabetes medication liraglutide ineffective in sufferers with advanced heart failureType 2 diabetes drug significantly reduces hospitalizations, death from heart failure Moreover, 12 weeks after starting treatment, insulin use in the placebo group was greater than in the analysis group significantly, and those who received alefacept showed no significant increase in insulin use over the course of the trial, whereas those in the placebo group do.Historically, mealtime insulin therapy regimens experienced a number of limitations, including the risk of severe hypoglycemia, the likelihood of pounds gain, inadequate post-food glucose control, the necessity for complicated titration of insulin dosages in connection with meals and the need for shots. Additionally, therapies have not mimicked the organic time-actions profile of insulin normally seen in healthy individuals and presented issues in preserving compliance. AFREZZA is a novel, ultra rapid performing mealtime insulin therapy getting developed by MannKind Corporation for the treatment of adult sufferers with Type 1 and Type 2 diabetes for the control of hyperglycemia. It really is a drug-device mixture product, comprising AFREZZA Inhalation Powder pre-metered into single use dose cartridges and the light, discreet and easy-to-make use of AFREZZA Inhaler.